| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1141.13% | -3440.23% | -1602.54% | — | — | — | — | -314.88% | -59.70% | -65.56% | -84.60% | -97.26% |
| EBITDA Margin | -1108.10% | -3324.92% | -1495.42% | — | — | — | — | -294.26% | -46.21% | -52.69% | -74.38% | -82.78% |
| Net Margin | -2588.21% | -3216.18% | -1540.63% | 105.23% | -88.73% | -165.27% | -355.29% | -317.20% | -50.66% | -97.74% | -48.67% | -113.75% |
| Current Ratio | 3.09 | 4.76 | 2.99 | 1.50 | 4.52 | 3.54 | 1.91 | 4.64 | 1.92 | 3.33 | 4.27 | 3.68 |
| Quick Ratio | 3.09 | 4.76 | 2.99 | 1.50 | 4.52 | 3.54 | 1.91 | 4.64 | 1.92 | 3.33 | 4.27 | 3.68 |
| Debt / Equity | 4.46 | 0.00 | 0.00 | 0.34 | 1.71 | 2.56 | 3.04 | 0.56 | 0.01 | 0.01 | 0.01 | 0.03 |
| ROE | -1198.61% | -327.77% | -80.93% | 22.43% | -85.86% | -253.85% | -449.48% | -134.49% | -21.41% | -32.78% | -11.99% | -19.99% |
| ROA | -161.18% | -86.90% | -63.49% | 13.11% | -25.61% | -54.20% | -70.72% | -71.12% | -13.82% | -19.66% | -8.60% | -14.20% |
| Asset Turnover | 0.06 | 0.03 | 0.04 | 0.12 | 0.29 | 0.33 | 0.20 | 0.22 | 0.27 | 0.20 | 0.18 | 0.12 |
| Book Value / Share | 0.07 | 0.14 | 0.48 | 0.63 | 0.54 | 0.40 | 0.47 | 2.92 | 4.55 | 4.82 | 6.35 | 4.13 |
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company operates through two primary business segments: Biopharmaceuticals and Exemplar. Precigen's therapeutic platforms include the AdenoVerse platform, which leverages a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and UltraCAR-T, which provides chimeric antigen receptor T cell therapies for cancer patients. A significant milestone in the company's development includes FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), the first and only approved therapy for treating adults with recurrent respiratory papillomatosis, a rare and debilitating chronic respiratory disease. Founded in 1998 and headquartered in Germantown, Maryland, Precigen represents an emerging player in the precision medicine sector, combining innovative gene therapy approaches with immunotherapy strategies.